Endo Sweats On Vasostrict Competition While Varenicline Is A Boon
Sterile Injectable Unit Impaired By Hundreds Of Millions Of Dollars
Executive Summary
Endo management turned talk once again to its expectations for Vasostrict competition in the coming months during its year-end earnings call. The US-based firm enjoyed a better end to the year as it capitalized on the opportunity for shortage-hit varenicline.